GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satsuma Pharmaceuticals Inc (NAS:STSA) » Definitions » YoY EPS Growth

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) YoY EPS Growth : 36.73% (As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Satsuma Pharmaceuticals YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Satsuma Pharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2023 was 36.73%.

Satsuma Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was $-0.31.

Satsuma Pharmaceuticals YoY EPS Growth Historical Data

The historical data trend for Satsuma Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satsuma Pharmaceuticals YoY EPS Growth Chart

Satsuma Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EPS Growth
Get a 7-Day Free Trial -42.11 -344.44 43.13 35.90 -25.14

Satsuma Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 -36.84 -14.29 -42.86 36.73

Satsuma Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Satsuma Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EPS Growth (A: Dec. 2022 )
=(Earnings per Share (Diluted) (A: Dec. 2022 )-Earnings per Share (Diluted) (A: Dec. 2021 ))/ | Earnings per Share (Diluted) (A: Dec. 2021 ) |
=(-2.19--1.75)/ | -1.75 |
=-25.14 %

Satsuma Pharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2023 is calculated as:

YoY EPS Growth (Q: Mar. 2023 )
=(Earnings per Share (Diluted) (Q: Mar. 2023 )-Earnings per Share (Diluted) (Q: Mar. 2022 )) / | Earnings per Share (Diluted) (Q: Mar. 2022 )) |
=(-0.31--0.49)/ | -0.49 |
=36.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Satsuma Pharmaceuticals YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Satsuma Pharmaceuticals's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satsuma Pharmaceuticals Inc (NAS:STSA) » Definitions » YoY EPS Growth
Comparable Companies
SURF CRTX CSBR LJPC EVLO FNCH PRTK DARE NXTC RZLT OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 221, South San Francisco, CA, USA, 94080
Website
https://www.satsumarx.com
Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Executives
Mutya Harsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Shin Nippon Biomedical Laboratories, Ltd. 10 percent owner 2438 MIYANOURA-MACHI, KAGOSHIMA CITY, KAGOSHIMA M0 891-1394
Thomas P Soloway director C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Ken Takanashi director, 10 percent owner C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Detlef Albrecht officer: Chief Medical Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Thomas P. O'neil officer: Chief Financial Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
John A Kollins director, officer: President and CEO SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080